We have advised Cell Therapy and Technology S.A. de C.V. on the patent case Pirfenidone Composition and procedure for the manufacture of prolonged release tablets.
This patent offers advantages and better therapeutic efficacy over other pharmaceutical forms of Pirfenidone for its oral administration and its therapeutic application in the regression of chronic renal failure secondary to primary glomerosclerosis; It has a better activity in the reduction and/or regression of the harmful effects in the mammary capsular contact observed after the surgical implantation of mammary implants.
Resolution is pending
